Personal Information
Entreprise/Lieu de travail
London United Kingdom
Profession
Economist
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
chrissampson.me
À propos
I'm a health economist exploring as many avenues of the subject as possible, currently resisting specialisation. I rarely pass up an opportunity on the grounds that I lack experience, and I'm always keen to get my head around new topics and approaches.
Mots-clés
article alerts
collaboration
pdfs
researchgate
research
academia
academis.edu
researcherid
thomson reuters
researchers
orcid
scopus
identity
sciverse
google scholar
citations
impact
web
university of nottingham
internet
medical physics
microeconomics
economic evaluation
social science
qaly
extra-welfarism
equity
efficiency
kenneth arrow
nhs
ethics
media
nice
medicine
alan williams
physics
supply and demand
health
health care
health economics
Tout plus
- Présentations
- Documents
- Infographies
Building Bridges Not Walls: Can We Develop Sustainable and Sharable Cost-Effectiveness Models?
Office of Health Economics
•
il y a 5 ans
Legal barriers to better use of health data to deliver pharmaceutical innovation
Office of Health Economics
•
il y a 5 ans
End of life treatments, societal values, and selecting a measure of 'overall' preference
Office of Health Economics
•
il y a 5 ans
Generating preference-based values for the EQ-5D-Y to support its use in HTA
Office of Health Economics
•
il y a 5 ans
OHE Lecturing for Professional Training at International Centre of Parliamentary Studies
Office of Health Economics
•
il y a 5 ans
Value of Diagnostic Information (VODI) from Concept to Reality. Socio-economic aspects of Value of Knowing
Office of Health Economics
•
il y a 5 ans
Should Drug Prices Differ by Indication? Outlining the debate on indication-based pricing and how it has been implemented to date
Office of Health Economics
•
il y a 5 ans
The Economics of Innovative Payment Models for Cancer Drugs: We Can Do Better
Office of Health Economics
•
il y a 5 ans
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public’s Preferences
Office of Health Economics
•
il y a 5 ans
Do EQ-5D-3L and EQ-5D-5L Capture the Same Changes in Quality of Life Over Time? A Longitudinal Study of Cancer Patients
Office of Health Economics
•
il y a 5 ans
Towards a Value Framework for Antibiotics
Office of Health Economics
•
il y a 6 ans
Estimating the Effect of Personal Experience and Vicarious Experience on Time Trade-Off Valuations of Health States.
Office of Health Economics
•
il y a 5 ans
What Outcomes Matter in Cancer? A Literature Review
Office of Health Economics
•
il y a 5 ans
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
Office of Health Economics
•
il y a 5 ans
Do EQ-5D-3L and EQ-5D-5L Capture the Same Changes in Quality of Life Over Time? A Longitudinal Study of Cancer Patients.
Office of Health Economics
•
il y a 5 ans
Understanding What Aspects of Health and Quality of Life Are Important to People
Office of Health Economics
•
il y a 6 ans
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
Office of Health Economics
•
il y a 6 ans
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Office of Health Economics
•
il y a 8 ans
VBP_in_UK_strengths_weakness
Office of Health Economics
•
il y a 8 ans
Measuring and valuing patient reported health_RSS
Office of Health Economics
•
il y a 8 ans